Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.
Tameris M, Mearns H, Penn-Nicholson A, Gregg Y, Bilek N, Mabwe S, Geldenhuys H, Shenje J, Luabeya AKK, Murillo I, Doce J, Aguilo N, Marinova D, Puentes E, Rodríguez E, Gonzalo-Asensio J, Fritzell B, Thole J, Martin C, Scriba TJ, Hatherill M; MTBVAC Clinical Trial Team. Tameris M, et al. Among authors: fritzell b. Lancet Respir Med. 2019 Sep;7(9):757-770. doi: 10.1016/S2213-2600(19)30251-6. Epub 2019 Aug 12. Lancet Respir Med. 2019. PMID: 31416768 Clinical Trial.
WHO preferred product characteristics for new vaccines against tuberculosis.
Schrager LK, Chandrasekaran P, Fritzell BH, Hatherill M, Lambert PH, McShane H, Tornieporth N, Vekemans J. Schrager LK, et al. Among authors: fritzell bh. Lancet Infect Dis. 2018 Aug;18(8):828-829. doi: 10.1016/S1473-3099(18)30421-3. Lancet Infect Dis. 2018. PMID: 30064668 No abstract available.
Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations.
Vekemans J, Brennan MJ, Hatherill M, Schrager L, Fritzell B, Rutkowski K, De Vos B, Zignol M, Thiry G, Ginsberg AM, Walker B. Vekemans J, et al. Among authors: fritzell b. Vaccine. 2020 Jan 10;38(2):135-142. doi: 10.1016/j.vaccine.2019.10.072. Epub 2019 Nov 13. Vaccine. 2020. PMID: 31733944 Free article. Review.
The TB vaccine development pathway - An innovative approach to accelerating global TB vaccine development.
Roordink D, Williams A, Fritzell B, Laddy DJ, Gerdil E, Graffin AM, Tait D, van der Pol L, van den Brink I, Holleman M, Thole J, Voss G, Lempicki M, Thiry G. Roordink D, et al. Among authors: fritzell b. Tuberculosis (Edinb). 2021 Jan;126:102040. doi: 10.1016/j.tube.2020.102040. Epub 2020 Dec 8. Tuberculosis (Edinb). 2021. PMID: 33310626 Free PMC article.
The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age.
Ferreccio C, Clemens J, Avendano A, Horwitz I, Flores C, Avila L, Cayazzo M, Fritzell B, Cadoz M, Levine M. Ferreccio C, et al. Among authors: fritzell b. Pediatr Infect Dis J. 1991 Oct;10(10):764-71. doi: 10.1097/00006454-199110000-00009. Pediatr Infect Dis J. 1991. PMID: 1945579 Clinical Trial.
Safety and immunogenicity in young infants of Haemophilus b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis-enhanced inactivated poliovirus vaccine.
Dagan R, Botujansky C, Watemberg N, Arbelli Y, Belmaker I, Ethevenaux C, Fritzell B. Dagan R, et al. Among authors: fritzell b. Pediatr Infect Dis J. 1994 May;13(5):356-62. doi: 10.1097/00006454-199405000-00005. Pediatr Infect Dis J. 1994. PMID: 8072816 Clinical Trial.
97 results